Skip to main content

Dr. Palladino has concentrated his research efforts on defining the biological interactions of cytokines and growth factors in inflammatory diseases and cancer. He received his Ph.D from New York University and after completing postdoctoral training at Memorial Sloan Kettering Cancer Center, joined Genentech where he held multiple positions including Director of both Cell Biology and Research Strategies. As Vice President of Preclinical Development at Applied Molecular Evolution, he directed an antibody based angiogenesis inhibitor program, Vitaxin that lead to the initiation of phase I clinical trials and the purchase of the company by Eli Lilly. Dr. Palladino recently served as Chief Technical Officer, Senior Vice President and was Co-founder of Nereus Pharmaceuticals, a biopharmaceutical company in San Diego (that raised) over $175M in funding focused on developing small molecules isolated from unique marine microorganisms to treat cancer, inflammation and infectious diseases. Nereus progressed the development of two programs into Phase I and II clinical trials in solid tumor and hematologic cancers. The lead proteasome inhibitor project, marizomib, is being funded by Celgene, a NJ Company. Dr. Palladino has over 250 publications in leading journals, over 50 patents/applications, has served as editor for leading scientific journals such as Cancer Research and the Journal of Immunology and co-organized multiple international meetings/sessions in cancer and inflammation for societies such as the AAI and AACR.